- Home
- NPCE vs ANNX Comparison
NPCE vs ANNX Comparison
Compare NPCE & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- ANNX
- Stock Information
- Founded
- NPCE 1997
- ANNX 2011
- Country
- NPCE United States
- ANNX United States
- Employees
- NPCE N/A
- ANNX N/A
- Industry
- NPCE Medical Specialities
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- NPCE Health Care
- ANNX Health Care
- Exchange
- NPCE Nasdaq
- ANNX Nasdaq
- Market Cap
- NPCE 339.6M
- ANNX 362.4M
- IPO Year
- NPCE 2021
- ANNX 2020
- Fundamental
- Price
- NPCE $11.15
- ANNX $1.88
- Analyst Decision
- NPCE Buy
- ANNX Strong Buy
- Analyst Count
- NPCE 6
- ANNX 5
- Target Price
- NPCE $14.83
- ANNX $18.67
- AVG Volume (30 Days)
- NPCE 167.9K
- ANNX 2.3M
- Earning Date
- NPCE 05-13-2025
- ANNX 05-12-2025
- Dividend Yield
- NPCE N/A
- ANNX N/A
- EPS Growth
- NPCE N/A
- ANNX N/A
- EPS
- NPCE N/A
- ANNX N/A
- Revenue
- NPCE $79,906,000.00
- ANNX N/A
- Revenue This Year
- NPCE $19.53
- ANNX N/A
- Revenue Next Year
- NPCE $11.83
- ANNX N/A
- P/E Ratio
- NPCE N/A
- ANNX N/A
- Revenue Growth
- NPCE 22.14
- ANNX N/A
- 52 Week Low
- NPCE $5.45
- ANNX $1.29
- 52 Week High
- NPCE $15.11
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- NPCE 47.58
- ANNX 48.45
- Support Level
- NPCE $10.02
- ANNX $1.40
- Resistance Level
- NPCE $11.76
- ANNX $1.96
- Average True Range (ATR)
- NPCE 0.94
- ANNX 0.18
- MACD
- NPCE 0.02
- ANNX 0.09
- Stochastic Oscillator
- NPCE 45.23
- ANNX 88.15
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.